<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/322DDD33-7767-499D-B26C-E8DC0E14EC16"><gtr:id>322DDD33-7767-499D-B26C-E8DC0E14EC16</gtr:id><gtr:name>ExpreS2ion Biotechnologies</gtr:name><gtr:address><gtr:line1>Agern All? 1</gtr:line1><gtr:postCode>DK-2970</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/50D55E0F-2E98-4684-8014-EE3D547EF883"><gtr:id>50D55E0F-2E98-4684-8014-EE3D547EF883</gtr:id><gtr:name>BASF</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6C168531-28B2-40BE-A7A6-842A96FD01AD"><gtr:id>6C168531-28B2-40BE-A7A6-842A96FD01AD</gtr:id><gtr:name>Redx Pharma Plc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FB887F7B-10EF-4A1F-944E-78328331F033"><gtr:id>FB887F7B-10EF-4A1F-944E-78328331F033</gtr:id><gtr:name>University of Foggia</gtr:name><gtr:address><gtr:line1>89-91, Antonio Gramsci Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/44BCECCF-49CB-46D7-BAA3-5B18144B0916"><gtr:id>44BCECCF-49CB-46D7-BAA3-5B18144B0916</gtr:id><gtr:name>Malaria GIA Reference Center - PATH MVI</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F4E9964B-E1BB-42CB-B2B9-998086AE0EF5"><gtr:id>F4E9964B-E1BB-42CB-B2B9-998086AE0EF5</gtr:id><gtr:name>BioGene</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8444DB3E-783B-4C59-9442-214102490F78"><gtr:id>8444DB3E-783B-4C59-9442-214102490F78</gtr:id><gtr:name>Natural History Museum</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/322DDD33-7767-499D-B26C-E8DC0E14EC16"><gtr:id>322DDD33-7767-499D-B26C-E8DC0E14EC16</gtr:id><gtr:name>ExpreS2ion Biotechnologies</gtr:name><gtr:address><gtr:line1>Agern All? 1</gtr:line1><gtr:postCode>DK-2970</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/50D55E0F-2E98-4684-8014-EE3D547EF883"><gtr:id>50D55E0F-2E98-4684-8014-EE3D547EF883</gtr:id><gtr:name>BASF</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6C168531-28B2-40BE-A7A6-842A96FD01AD"><gtr:id>6C168531-28B2-40BE-A7A6-842A96FD01AD</gtr:id><gtr:name>Redx Pharma Plc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FB887F7B-10EF-4A1F-944E-78328331F033"><gtr:id>FB887F7B-10EF-4A1F-944E-78328331F033</gtr:id><gtr:name>University of Foggia</gtr:name><gtr:address><gtr:line1>89-91, Antonio Gramsci Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/44BCECCF-49CB-46D7-BAA3-5B18144B0916"><gtr:id>44BCECCF-49CB-46D7-BAA3-5B18144B0916</gtr:id><gtr:name>Malaria GIA Reference Center - PATH MVI</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F4E9964B-E1BB-42CB-B2B9-998086AE0EF5"><gtr:id>F4E9964B-E1BB-42CB-B2B9-998086AE0EF5</gtr:id><gtr:name>BioGene</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8444DB3E-783B-4C59-9442-214102490F78"><gtr:id>8444DB3E-783B-4C59-9442-214102490F78</gtr:id><gtr:name>Natural History Museum</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F76750E6-D3E0-49FE-AF75-EEDEE61210D9"><gtr:id>F76750E6-D3E0-49FE-AF75-EEDEE61210D9</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Croft</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C943CC76-B042-406D-A1CB-E97710EF626F"><gtr:id>C943CC76-B042-406D-A1CB-E97710EF626F</gtr:id><gtr:firstName>Giancarlo</gtr:firstName><gtr:otherNames>Augusto</gtr:otherNames><gtr:surname>Biagini</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/35C0CE50-61C8-4951-A6BD-C121ABC82F8E"><gtr:id>35C0CE50-61C8-4951-A6BD-C121ABC82F8E</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Ward</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/72056FF9-D3CE-4186-BD73-491ABDB4EA85"><gtr:id>72056FF9-D3CE-4186-BD73-491ABDB4EA85</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Draper</gtr:surname><gtr:orcidId>0000-0002-9415-1357</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15040"><gtr:id>58D5CE6A-81E2-4995-B56C-8B7C69D8E351</gtr:id><gtr:title>Tropical Infectious Disease Consortium: Expanding and Accelerating Product Development</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15040</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>500000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Foggia</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Biomedical Sciences</gtr:department><gtr:description>Dr Edward Wright- generation of unique reagents necessary to facilitate works</gtr:description><gtr:id>32FB1048-7943-451C-8C56-5BE32B6D1EEC</gtr:id><gtr:impact>Collaboration in progress - works discussed in detail.
Reagents already shared to facilitate generation of novel reagents to assess immunogenicity post vaccination with novel (to be generated) vaccines toward emerging pathogens.</gtr:impact><gtr:outcomeId>57d80d4e9ddb00.12576260-1</gtr:outcomeId><gtr:partnerContribution>Collaboration in progress - works discussed in detail.</gtr:partnerContribution><gtr:piContribution>Co-Applicant, expert in field for generation of necessary resources to facilitate works.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Malaria GIA Reference Center - PATH MVI</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GIA Reference Centre, NIH</gtr:description><gtr:id>31CCA284-EEAF-4D26-98F1-B156D857CFEA</gtr:id><gtr:impact>Publications.
PMID: 20713623
PMID: 21698193
PMID: 21799809
PMID: 21862998
PMID: 22186897
PMID: 22363582
PMID: 22984589
PMID: 23089736
PMID: 23144611
PMID: 23872520

Joint PhD student.</gtr:impact><gtr:outcomeId>UXWgj7XYbDC-1</gtr:outcomeId><gtr:partnerContribution>Significant experimental input.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>Contract established with Oslo University</gtr:description><gtr:id>7AA53F10-1800-4DEF-91DB-E5517AA1A0EB</gtr:id><gtr:impact>Contract
Project still in progress</gtr:impact><gtr:outcomeId>57d2a49fd1fa36.09814873-1</gtr:outcomeId><gtr:partnerContribution>This is essentially a UoO project that we are now feeding into. While technically separate from the CIC award, should we be successful this work would benefit future work of the CIC project.</gtr:partnerContribution><gtr:piContribution>During the development of the CIC grant a gap was identified in one of the University of Oslo's grants that could be filled in this collaboration. This has brought the two teams working closer together on other aspects of the work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Engineering</gtr:department><gtr:description>University of Warwick</gtr:description><gtr:id>BBDFB38C-9661-46A5-92EF-94612E770030</gtr:id><gtr:impact>University of Warwick - Engineering
LSTM - Medical Entomology / animal behaviour</gtr:impact><gtr:outcomeId>57e2bb8b59b353.85515515-1</gtr:outcomeId><gtr:partnerContribution>All behavioural assays recorded to date have been performed using technology designed and purpose-built by the applicants. The tracking software, recording system and subsequent analytical software were all produced in close collaboration with the team of engineers at the University of Warwick. Currently, this analytical software is being tested and improved alongside the modelling work. Data used during model parametrisation is thoroughly tested and so can inform the investigation into biases or inconsistencies in the original analysis software.</gtr:partnerContribution><gtr:piContribution>The underlying data and information used to create the parameters for the simulation have been recorded by the named applicants as part of previous investigations into mosquito host-seeking behaviour. The behavioural assays that have been recorded to date were designed and executed by the researchers at the LSTM and made possible by the engineers at the University of Warwick. This collaboration is now developing further, as the work made possible by this award has allowed Dr Jeff Jones of the LSTM to collaborate with Dr Vitaly Voloshin of Warwick in order to re-code and improve the previous software used during video analysis. Further to this, the classification of host-seeking behaviour for use in the model will inform the re-design of the tracking software in terms of modes of mosquito behaviour that can be exploited when analysing video footage. As of January 2017 a microsoft sharespace site has been established to enable the sharing of data, information and discussions relating to these and similar projects, created by Dr Greg Murray and hosted by the LSTM.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Redx Pharma Plc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Joint PhD Student with RedX Pharma</gtr:description><gtr:id>E7E698F8-199C-401D-A1E5-4D55C792BC0C</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>58221c2081c7b2.17772327-1</gtr:outcomeId><gtr:partnerContribution>This is a joint initiative between LSTM and RedX Pharma to recruit a PhD student to undertake a project at Liverpool and Alderley Park</gtr:partnerContribution><gtr:piContribution>This is a joint initiative between LSTM and RedX Pharma to recruit a PhD student to undertake a project at Liverpool and Alderley Park</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ExpreS2ion Biotechnologies</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>ExpreS2ion Bio</gtr:description><gtr:id>2D3122A9-B247-4E17-AD19-4813C3A1B43E</gtr:id><gtr:impact>MRC DPFS grant awarded.
European Vaccine Initiative grant awarded.
PATH Malaria Vaccine Initiative grant awarded</gtr:impact><gtr:outcomeId>SBxLpZawsv4-1</gtr:outcomeId><gtr:partnerContribution>Access to research reagents.
Grant collaborator.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BASF</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>BASF Plant Science</gtr:department><gtr:description>BASF Cfp probes</gtr:description><gtr:id>9BBBA897-2BF9-4084-A45F-0A79CB5A7AFE</gtr:id><gtr:impact>Publication and grant application drafts - expected submission mid 2017.</gtr:impact><gtr:outcomeId>58bd6ed5ed1471.44352216-1</gtr:outcomeId><gtr:partnerContribution>Provided mosquito membrane extracts for biologocal assays</gtr:partnerContribution><gtr:piContribution>Developing doagnostic probes for chlorfenapyr (BASF compound)</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Obstetrics &amp; Gynaecology</gtr:department><gtr:description>SpyTag-SpyCatcher with Prof Mark Howarth</gtr:description><gtr:id>21E1AA1F-D155-482B-B3A0-72F4BA5FE6BC</gtr:id><gtr:impact>Publications and grants</gtr:impact><gtr:outcomeId>58a33e42182577.77086573-1</gtr:outcomeId><gtr:partnerContribution>Development of SpyTag-SpyCatcher technology</gtr:partnerContribution><gtr:piContribution>Development of new VLP malaria vaccines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Natural History Museum</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Library and Archives</gtr:department><gtr:description>Natural History Museum- assay development</gtr:description><gtr:id>F47B2563-4F6A-463B-84DE-88E00280B1B9</gtr:id><gtr:impact>Not yet.</gtr:impact><gtr:outcomeId>58c812225854c6.03414762-1</gtr:outcomeId><gtr:partnerContribution>My team works closely with Dr. Bonnie Webster's team at the NHM in optimising the Giardia RPA assay. Dr. Webster developed the RPA for Schistosoma haematobium in 2016 and has been instrumental in troubleshooting hurdles found along the way. Dr. Webster has also provided equipment and instruments needed for the assay development.

Future projects with the NHM include a multiplex RPA for Giardia- Schistosoma mansoni.</gtr:partnerContribution><gtr:piContribution>We have shared the protocol development of the assay with Dr. Bonnie Webster and her team at the NHM.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BioGene</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BioGene and QuRapID qPCR system</gtr:description><gtr:id>B87D1AD0-DD32-4B4E-91CA-66F80CB09012</gtr:id><gtr:impact>Publications have been added to relevant section on research fish. 
IP file in preparation for arboviral assay</gtr:impact><gtr:outcomeId>58b82c9cdfcc95.33902499-1</gtr:outcomeId><gtr:partnerContribution>Use of Visual OMP for primer/probe design. 
Test rig of the QuRapID system delivered to LSTM
PhD student Kavit Shah will start in March 2017 (student and bench fees to LSTM)
Support with development of molecular system and transfer to qurapid.</gtr:partnerContribution><gtr:piContribution>Design of primer and probes sets for the identification of anti-microbial resistance markers. Collection of bacterial isolates with AMR markers in Malawi.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oxford University London Lecture 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CAB28F5D-7922-462D-A459-4A5AC47500BC</gtr:id><gtr:impact>This is a premier Oxford lecture each year presented at Westminster in London. I spoke on Ebola vaccines</gtr:impact><gtr:outcomeId>58c7c307e33023.43005683</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>VIT Visiting Adjunct Professor Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>606EA2DF-BF53-4088-B450-DBBDED1AD0E1</gtr:id><gtr:impact>Lectures given under Adjunct Visiting Professorship Scheme. Lecture covered new advances in disease control including MRC CiC related research on Adhirons, activity based probes and DNA based resistance diagnostics.</gtr:impact><gtr:outcomeId>58bd728805ccd9.73782144</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture on CiC progress-London School of Hygiene &amp; Tropical Medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DBF308C2-90CB-4757-8206-906CA694CB90</gtr:id><gtr:impact>50-75 people attended the update on the RPA assay development. The results were well received and there was some interesting feedback on the project.</gtr:impact><gtr:outcomeId>58c8101e852a94.70363318</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Attendance DHIS2 experts meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C0F01CB3-7252-4CF8-AF4B-F647951DDD1F</gtr:id><gtr:impact>This was an opportunity for LSTM to present its work, the DDMS, to the experts in the DHIS2 community whom we intend to collaborate and merge with. How this can potentially be achieved, the benefits and the challenges were presented and discussed.</gtr:impact><gtr:outcomeId>57d2a6e55faf51.82514986</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GAP analysis</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>ED71AEA9-1A28-49C4-A64A-C9E692AB2B96</gtr:id><gtr:impact>The purpose of this engagement was to look at the two system, DDMS and DHIS2 and produce the GAP analysis (Mile stone 1 of the CIC project). This has now been completed.</gtr:impact><gtr:outcomeId>57d2a7df4163a0.52494681</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the MMV External Scientific Advisory Board 2017 to date</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>51A6B3C6-B84F-4B9F-AF10-D20EA95725DC</gtr:id><gtr:outcomeId>58c7ce99550d66.70277946</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>External advice to major funder with regard to antimalarial drug discovery projects</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>99CFC156-DF5E-4084-B475-B9BEF55BEA42</gtr:id><gtr:outcomeId>58221de4d4eb66.30605490</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>The development of an RPA for Giardia lamblia was published in 2016 (Cranell et al 2016) but never field-tested for the full assay or validated in an African context and as a field-applicable diagnostic tool to document treatment efficacy. This current project will address those gaps by refining the RPA field-test it and will provide analytical and clinical outputs by the end of 2017.

The RPA assay will be field tested in a rural setting in Uganda in June- July 2017.</gtr:description><gtr:id>25715A0C-F861-4EC2-AD4F-361D2F0BC853</gtr:id><gtr:impact>The expected outcomes of this project will be to improve on-site highly sensitive diagnosis of giardiasis and provide a reliable and low cost test-of-cure in an underdevelop African country.</gtr:impact><gtr:outcomeId>5898d8c0237e31.46753759</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Recombinase Polymerase Assay for Giardiasis</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://www.twistdx.co.uk/our_technology/</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We have developed a unique tracking system to observe and track mosquito behaviour at human-baited bednets in the laboratory using infra-red cameras, automated video analysis, tracking and data handling software. This approach has provided new insights into vector behaviour and has allowed host-seeking behaviour to be recorded and classified into behavioural parameters. 

These parameters, in combination, constitute basic host-seeking behaviour at a human-occupied bednet with each parameter playing an important role in the efficacy of any vector control methods. By analysis of flight paths, we identified key elements of mosquito host-seeking behaviour. For example the frequency, duration and type of contact with the bednet, flight speed, tortuosity and classification of different types of host-seeking behaviour. 

We are using this information described above to identify behavioural parameters that can be incorporated into existing, freely available individual-based model (IBM) framework software. Existing data that describe basic mosquito host-seeking behaviour are already well established through video-tracking of behavioural assays conducted by our group. Further information is available in the literature as part of larger-scale, epidemiology-focused mosquito individual-based models, focusing on the landscape-scale.

Currently a full suite of parameters is being collated and the model is being assembled using existing standardized frameworks namely processing programming language and the NetLogo platform. These modelling systems use high-level coding languages and as such are relatively accessible to novice users. Further they have wide user-bases and precedents exist for their use in small-scale spatial modelling, especially for NetLogo. Moreover, both systems allow for the incorporation of an easy to use graphic user interface to allow the quick roll-out and uptake of the simulation system for the testing and screening of potential new vector control methods, initially centred around LLIN designs, where our current expertise is most evident.

Dr Jeff Jones has recently started this work and by collaborating with Dr Greg Murray of the LSTM, Dr Christian Kroner and Dr Vitaly Voloshin of Warwick University he aims to make use of both the currently existing tracking information as well as more recent developments in the filming and analysis system as well as previously collected data on window entry and contact irritancy behaviour as evidenced through small-scale thumb-test behavioural assays. Currently he is creating the modelled system in both two and three dimensions in order to assess the compromise between model utility and complexity, especially given the increased computer time associated with modelling in three dimensions. Further to this Dr Jones' level of technical ability and experience in biological computing is greater than one would expect for the advertised role, therefore are considering how best to stream-line the process of model validation and use with an eye on potential further developments, for example modelling other strains or species of mosquitoes.</gtr:description><gtr:id>79B6AD5A-7F8D-48A8-8E34-E165A4869A39</gtr:id><gtr:impact>This project aims to provide an in silico testing environment that could assess new insecticide net treatments, or alternative net structures quickly and cheaply. The Individual Based Model would use data from small scale behavioural tests to estimate the efficacy of different control options (e.g. insecticide concentrations, net designs, different active chemicals, etc.) and provide outputs of expected efficacy against a specified mosquito population (e.g. contact time, probable mortality, locations of highest surface contact). LLIN designs that proved effective in the virtual lab would then be taken forward for larger scale field evaluation with a significant improvement in expectation of a demonstrable impact.

Continued control of mosquito vectors will require constant innovation as the global health community works to combat the growing problem of insecticide resistance. This virtual testing environment will facilitate design and evaluation of new control methods, helping speed up the process of getting new nets from lab to the field.

Once the system has been designed and tested for use with LLINs it may be expanded for application to other interventions such as eave tubes or window screens. The intervention will be trialled with data on Anopheles gambiae s.s. but has potential to further incorporate responses of various vector species.</gtr:impact><gtr:outcomeId>57e2bee9d9ede5.45799100</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>InFlITE</gtr:title><gtr:type>Computer model/algorithm</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The Recombinase Polymerase Assay (RPA) is an isothermal DNA amplification assay that employs enzymes, known as recombinases, which are capable of pairing oligonucleotide primers with homologous sequence in duplex DNA. Through this method, DNA synthesis is directed to defined points in a sample DNA. If the target sequence is indeed present, DNA amplification reaction is initiated; no other sample manipulation such as thermal or chemical melting is required. The reaction progresses rapidly and results in specific DNA amplification from just a few target copies to detectable levels typically within 3 - 10 minutes. The entire reaction system is stable as a dried formulation and can be transported safely without refrigeration. It is set to become a feasible point-of-care molecular diagnostic assay to be used in resource limited areas. 

The RPA for Giardia spp. proposed in this project is amplifying sequences from the ?-giardin gene. A specific FAM-labelled probe and biotin-labelled primer are used to generate an amplicon at 37&amp;deg;C, resulting in a specific, dual-labelled product; this can be monitored visually via its binding to a biotin ligand on a lateral flow strip with concurrent gold-labelled anti-FAM detection. 

Currently, we have successfully applied RPA to identify ?-giardin sequences from trophozoite-extracted DNA which have been confirmed by sequencing. At the moment we are refining this technique using Giardia duodenalis inactivated cysts (H3 isolate, Waterborne Inc, New Orleans , USA) spiking negative stool samples. Additionally, we are developing methods of multiplexing assays to characterize the assemblage(s) of Giardia duodenalis from infected people, and from environmental sampling, to further understand clinical associations and natural cycles of transmission of the various assemblages. Going forward, we intend to devise a multiplex test of Giardia duodenalis and Schistosoma mansoni, which are co-endemic.

Comparison to other molecular tools: Real time PCR and droplet digital PCR (ddPCR).</gtr:description><gtr:id>ACBECC56-0320-4F35-88A1-6861062780E8</gtr:id><gtr:impact>Rapid diagnosis and treatment
G. lamblia genotype-specific RPA will allow access to prompt diagnosis and treatment of children harbouring light and moderate infections not currently detected by available methods. The ability to detect genotypes associated with negative health outcomes will have its highest applicability in field surveys. It also has the potential to be used in institutional outbreaks where G. lamblia is known to occur (Baque et al., 2011). The development of a new genotype-specific RPA Giardia assay can be used and adopted by many groups across institutions nationally (LSHTM, LSTM) as well as internationally. The internal and external validation of the proposed work will be essential in technology transfer for a generalized use. Comparison for test validity against real-time PCR will produce robust sensitivity and specificity outcomes of the test that can act as reference for further use. 

Feasibility of use in low-resource settings
RPA is a validated assay used for the detection of different pathogens (Rosser et al., 2015). The recombinase polymerase reaction can take place at an ambient temperature (Krolov et al., 2014), reagents are lyophilized making its use feasible in extreme temperatures. DNA amplification can be detected by visual reading of lateral flow (LF) strips, allowing flexibility in resource limited settings (Kersting et al, 2014).

New endpoint for clinical trials
There are ongoing trials to develop a single dose treatment that would mainstream treatment and allow mass drug administration for G. lamblia. Real-time PCR is the most sensitive test of cure, but limitations include high cost, skilled personnel, and reagents that need refrigeration. Infection clearance by POC-RPA has the potential to become a new endpoint for drug trials.</gtr:impact><gtr:outcomeId>5898d73f4a40d7.91804432</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Recombinase Polymerase Assay for Giardiasis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.twistdx.co.uk/</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Photoactivated chermical probe for chlorfenapyr.</gtr:description><gtr:id>8B6857FD-F241-4B6F-A7E9-BB0CACCC70E3</gtr:id><gtr:impact>Probe recently synthesised, will be used for identifiying chlorfenapyr binding proteins in mosquitoes in next 4 four months. This is the first of a suite of new activity probes for tracking insecticide targets and metabolic enzymes associated with detoxification (resistance).</gtr:impact><gtr:outcomeId>58bd75abbadaa5.13481632</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cfp photoactive probe</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Structure of RH5 malaria protein for design of new vaccines and small molecule inhibitors</gtr:description><gtr:id>9E2CF517-FD8E-4F59-B929-7C928B67116B</gtr:id><gtr:impact>Published</gtr:impact><gtr:outcomeId>5463b118c838e2.79603908</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RH5 structure</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/25132548</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>728B2689-1F31-4301-B5F0-ED2D8B151DBC</gtr:id><gtr:title>A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>582445d8e08c69.72871232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBAE2FA4-9819-4B4E-A188-FB1E6883796A</gtr:id><gtr:title>Corrigendum: A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>58c7cda72f7a50.40072733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3D033FA-D9AE-4498-BF72-11E88196068D</gtr:id><gtr:title>Influence of theGene on In Vitro Sensitivities of Piperaquine in Thai Isolates of.</gtr:title><gtr:parentPublicationTitle>The American journal of tropical medicine and hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/690909a391a0c1aab3ba74b8b327a637"><gtr:id>690909a391a0c1aab3ba74b8b327a637</gtr:id><gtr:otherNames>Mungthin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9637</gtr:issn><gtr:outcomeId>58c7cda78786e3.48202906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFE8E06D-BFA3-44F6-893A-2CD795B6A585</gtr:id><gtr:title>A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a06c05b3620f7d7cdab1f4b38cdaeaef"><gtr:id>a06c05b3620f7d7cdab1f4b38cdaeaef</gtr:id><gtr:otherNames>O'Neill PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a98259f0527f7.99135589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC10E5B0-60CE-44AB-8A61-7AD0706DF171</gtr:id><gtr:title>Analytical and clinical performance of a Chikungunya qRT-PCR for Central and South America.</gtr:title><gtr:parentPublicationTitle>Diagnostic microbiology and infectious disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45e39a0a2ca997212fee6634c32644e5"><gtr:id>45e39a0a2ca997212fee6634c32644e5</gtr:id><gtr:otherNames>Edwards T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0732-8893</gtr:issn><gtr:outcomeId>5aaa85fc9412b4.38038612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B520BB65-90FF-412D-B025-3B579CBC5B66</gtr:id><gtr:title>A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a06c05b3620f7d7cdab1f4b38cdaeaef"><gtr:id>a06c05b3620f7d7cdab1f4b38cdaeaef</gtr:id><gtr:otherNames>O'Neill PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a9ead1b184c34.70901898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F192626B-9CA2-415B-830E-44E34D4CB486</gtr:id><gtr:title>A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0044-8249</gtr:issn><gtr:outcomeId>582445d92037f5.81178827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E62BE8E8-E9CF-4C96-BA35-4EABEEDE4DF8</gtr:id><gtr:title>OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3511efcc710829c2226c3891942d74"><gtr:id>1e3511efcc710829c2226c3891942d74</gtr:id><gtr:otherNames>Aljayyoussi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>582445d93f6472.83443694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E118C4B8-34A4-4F36-80D8-5C2DE481EF9E</gtr:id><gtr:title>Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55ab1c40f6d33c3a39a4e51b6de09f45"><gtr:id>55ab1c40f6d33c3a39a4e51b6de09f45</gtr:id><gtr:otherNames>Slagboom J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>58b434bab09cd8.00062817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D05F7902-EE4F-4410-A5F9-3B29165F66A7</gtr:id><gtr:title>Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>582219d0dc3c80.24009746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEF19735-6E79-41AE-A6D2-85E17F7F787E</gtr:id><gtr:title>PFMDR1 POLYMORPHISMS INFLUENCE ON IN VITRO SENSITIVITY OF THAI PLASMODIUM FALCIPARUM ISOLATES TO PRIMAQUINE, SITAMAQUINE AND TAFENOQUINE.</gtr:title><gtr:parentPublicationTitle>The Southeast Asian journal of tropical medicine and public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6059000f7b5ed7c42535268802fac5a8"><gtr:id>6059000f7b5ed7c42535268802fac5a8</gtr:id><gtr:otherNames>Kaewpruk N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0125-1562</gtr:issn><gtr:outcomeId>582219d13bdb22.09954819</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15040</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>